Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.

Autor: Waterhouse DM; Oncology Hematology Care (OHC)/An affiliate of the US Oncology Network, Cincinnati OH., Ward P; Oncology Hematology Care (OHC)/An affiliate of the US Oncology Network, Cincinnati OH., Drosick DR; Oncology Hematology Care (OHC)/An affiliate of the US Oncology Network, Cincinnati OH., Burdette C; Oncology Hematology Care (OHC)/An affiliate of the US Oncology Network, Cincinnati OH., Davies D; Oncology Hematology Care (OHC)/An affiliate of the US Oncology Network, Cincinnati OH., Mendenhall MA; Oncology Hematology Care (OHC)/An affiliate of the US Oncology Network, Cincinnati OH.

Publikováno v: JCO oncology practice [JCO Oncol Pract] 2023 Nov; Vol. 19 (11), pp. 1053-1057. Date of Electronic Publication: 2023 Sep 22.

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

Autor: Yardley DA; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA. dyardley@tnonc.com.; Tennessee Oncology, Nashville, TN, USA. dyardley@tnonc.com., Arrowsmith ER; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA., Daniel BR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA., Eakle J; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Brufsky A; University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Drosick DR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Oncology Hematology Care, Cincinnati, OH, USA., Kudrik F; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; South Carolina Oncology Associates, Columbia, SC, USA., Bosserman LD; Wilshire Oncology Medical Group, La Verne, CA, USA., Keaton MR; Augusta Oncology Associates, Augusta, GA, USA., Goble SA; Virginia Cancer Institute, Richmond, VA, USA., Bubis JA; ICON/Cancer Specialists of North Florida, Jacksonville, FL, USA., Priego VM; Center for Cancer and Blood Disorder, Bethesda, MD, USA., Pendergrass K; Kansas City Cancer Center, Overland Park, KS, USA., Manalo Y; Costal Bend Cancer Center, Corpus Christi, TX, USA., Bury M; Cancer Research Consortium of West Michigan, Grand Rapids, MI, USA., Gravenor DS; Family Cancer Center, Memphis, TN, USA., Rodriguez GI; South Texas Oncology Hematology, San Antonio, TX, USA., Inhorn RC; Mercy Hospital, Portland, ME, USA., Young RR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; The Center for Cancer and Blood Disorders, Ft Worth, TX, USA., Harwin WN; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Silver C; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Hainsworth JD; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA., Burris HA 3rd; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2017 Aug; Vol. 164 (3), pp. 649-658. Date of Electronic Publication: 2017 May 15.

A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.

Autor: Yardley DA; Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA., Daniel D, Stipanov M, Drosick DR, Mainwaring M, Peyton J, Shastry M, Hainsworth JD

Publikováno v: Cancer investigation [Cancer Invest] 2010 Oct; Vol. 28 (8), pp. 865-71.